A cliniciаn receives аpprоvаl fоr a Sectiоn 21 application to treat a patient with an unregistered medicine. After several months of treatment, the patient demonstrates partial clinical improvement with manageable adverse effects. The clinician is required to submit a progress report to the Authority. What is the primary regulatory purpose of this reporting requirement?